Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 1
1991 1
1992 1
2001 1
2008 2
2009 1
2012 1
2014 1
2018 1
2019 1
2020 2
2021 4
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

18 results
Results by year
Filters applied: . Clear all
Page 1
Acute Kidney Injury Following Encorafenib and Binimetinib for Metastatic Melanoma.
Seethapathy H, Bates H, Chute DF, Strohbehn I, Strohbehn S, Fadden RM, Reynolds KL, Cohen JV, Sullivan RJ, Sise ME. Seethapathy H, et al. Among authors: fadden rm. Kidney Med. 2020 Apr 18;2(3):373-375. doi: 10.1016/j.xkme.2020.01.012. eCollection 2020 May-Jun. Kidney Med. 2020. PMID: 32734258 Free PMC article. No abstract available.
Evolution of delayed resistance to immunotherapy in a melanoma responder.
Liu D, Lin JR, Robitschek EJ, Kasumova GG, Heyde A, Shi A, Kraya A, Zhang G, Moll T, Frederick DT, Chen YA, Wang S, Schapiro D, Ho LL, Bi K, Sahu A, Mei S, Miao B, Sharova T, Alvarez-Breckenridge C, Stocking JH, Kim T, Fadden R, Lawrence D, Hoang MP, Cahill DP, Malehmir M, Nowak MA, Brastianos PK, Lian CG, Ruppin E, Izar B, Herlyn M, Van Allen EM, Nathanson K, Flaherty KT, Sullivan RJ, Kellis M, Sorger PK, Boland GM. Liu D, et al. Among authors: fadden r. Nat Med. 2021 Jun;27(6):985-992. doi: 10.1038/s41591-021-01331-8. Epub 2021 May 3. Nat Med. 2021. PMID: 33941922 Free PMC article.
Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib.
Seethapathy H, Lee MD, Strohbehn IA, Efe O, Rusibamayila N, Chute DF, Colvin RB, Rosales IA, Fadden RM, Reynolds KL, Sullivan RJ, Kaufman HL, Jhaveri KD, Sise ME. Seethapathy H, et al. Among authors: fadden rm. Nephrol Dial Transplant. 2020 Dec 23:gfaa372. doi: 10.1093/ndt/gfaa372. Online ahead of print. Nephrol Dial Transplant. 2020. PMID: 33355659
Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort.
Bai X, Kim M, Kasumova G, Si L, Tang B, Cui C, Yang X, Wei X, Cohen J, Lawrence D, Freedman C, Fadden R, Rubin K, Sharova T, Frederick D, Flaherty K, Sullivan R, Guo J, Boland G. Bai X, et al. Among authors: fadden r. J Immunother Cancer. 2021 Feb;9(2):e002092. doi: 10.1136/jitc-2020-002092. J Immunother Cancer. 2021. PMID: 33632901 Free PMC article.
Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy.
Bai X, Hu J, Betof Warner A, Quach HT, Cann CG, Zhang MZ, Si L, Tang B, Cui C, Yang X, Wei X, Pallan L, Harvey C, Manos MP, Ouyang O, Kim MS, Kasumova G, Cohen JV, Lawrence DP, Freedman C, Fadden RM, Rubin KM, Sharova T, Frederick DT, Flaherty KT, Rahma OE, Long GV, Menzies AM, Guo J, Shoushtari AN, Johnson DB, Sullivan RJ, Boland GM. Bai X, et al. Among authors: fadden rm. Clin Cancer Res. 2021 Nov 1;27(21):5993-6000. doi: 10.1158/1078-0432.CCR-21-1283. Epub 2021 Aug 10. Clin Cancer Res. 2021. PMID: 34376536 Free article.
18 results